Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
56.1M
-
Shares change
-
+16.6M
-
Total reported value, excl. options
-
$2.86B
-
Value change
-
+$861M
-
Number of buys
-
71
-
Number of sells
-
-15
-
Price
-
$51.00
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q2 2023
89 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q2 2023.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.1M shares
of 63.5M outstanding shares and own 88.29% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (8.14M shares), FMR LLC (3.38M shares), CITADEL ADVISORS LLC (2.02M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.94M shares), Avoro Capital Advisors LLC (1.73M shares), Polar Capital Holdings Plc (1.62M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.37M shares), FEDERATED HERMES, INC. (1.17M shares), and T. Rowe Price Investment Management, Inc. (1.15M shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.